Celcuity Inc. - Common Stock (NQ:CELC)

63.17 -0.87 (-1.35%)

Delayed Quote Updated: 9:43 AM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

What Celcuity (CELC) Said on Its Q3 Earnings Call ↗

November 05, 2026

Celcuity (NASDAQ:CELC) reported a wider third-quarter loss as it prepared to commercialize its breast cancer treatment REVTORPYK, while executives said early orders and insurance coverage pointed to an...

Via MarketBeat

Topics Earnings

Why Celcuity Stock Was a Winner on Wednesday ↗

September 30, 2026

Its first commercialized drug is now available for qualified patients.

Via The Motley Fool

Celcuity (CELC) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Revtopik launch underway with 80 oncology specialists supporting expansion into first-line treatment.

Via The Motley Fool

Topics Earnings

Celcuity Inc. (NASDAQ:CELC) Q1 Earnings Beat Forecasts, But Stock Drops on Phase 3 Data Focus ↗

May 14, 2026

Via Chartmill

Topics Earnings

Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib ↗

March 25, 2026

Via Chartmill

Topics Earnings

Celcuity Q2 Earnings Call Highlights ↗

August 13, 2026

Celcuity (NASDAQ:CELC) said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026...

Via MarketBeat

Topics Earnings

Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript ↗

August 13, 2026

On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call...

Via Benzinga

Topics Earnings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

August 04, 2026

From Pomerantz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm

August 04, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 03, 2026

From Kirby McInerney LLP

Via Business Wire

CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law

August 02, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

July 28, 2026

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

July 28, 2026

From Pomerantz LLP

Via GlobeNewswire

CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm

July 21, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

July 21, 2026

From Pomerantz LLP

Via GlobeNewswire

Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer ↗

July 15, 2026

Celcuity (NASDAQ:CELC) said the U.S. Food and Drug Administration has granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer, marking the...

Via MarketBeat

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗

June 19, 2026

Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....

Via InvestorPlace

Stay updated with the stocks that are on the move in today's pre-market session. ↗

June 02, 2026

Via Chartmill

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗

May 30, 2026

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

Via The Motley Fool

Topics Regulatory Compliance

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗

May 17, 2026

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗

May 17, 2026

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

Via The Motley Fool

Topics Regulatory Compliance

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗

May 17, 2026

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.

Via The Motley Fool

Celcuity Q1 Earnings Call Highlights ↗

May 14, 2026

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its...

Via MarketBeat

Topics Earnings

Celcuity (CELC) Q1 2026 Earnings Transcript ↗

May 14, 2026

Celcuity (CELC) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗

May 10, 2026

This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗

May 10, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.

Via The Motley Fool

Traders are paying attention to the gapping stocks in Monday's session. ↗

May 04, 2026

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

May 04, 2026

Via Chartmill

Why Celcuity Stock Popped on Monday ↗

April 27, 2026

An analyst initiated coverage of the biotech.

Via The Motley Fool

Why Celcuity Stock Popped Today ↗

March 26, 2026

The cancer-focused biotech published its final set of figures for 2025.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.